


AMENDMENTS TO THE CLAIMS

This list of claims replaces the claims in the application.

Claims 1-53 (canceled)

54. (currently amended) A compound having the structure IA



a prodrug of the compound, a pharmaceutically acceptable salt of the compound, a stereoisomer of the compound, a tautomer of the compound, or a solvate of the compound

wherein G is -C(O)-, =CR³ or -CR³R⁴;

wherein R³ and R⁴ are -H or one of R³ and R⁴ is -H and the other is -OH or substituted or unsubstituted lower alkoxy;

and the dashed lines in structure IA represent carbon-carbon double bonds or carbon-carbon single bonds contained within the fused four-ring system, such that the compound comprises a 1,6-diene, 1,7-diene, 1,8-diene, 1,15-diene, 4,8-diene, or a 3,16-diene within the fused four-ring system;

or G is -C(O)- or -CR³R⁴;

wherein R³ is -OH or substituted or unsubstituted lower alkoxy and R⁴ is -H;


and the dashed lines in structure IA represent carbon-carbon double bonds or carbon-carbon single bonds contained within the fused four-ring system, such that the compound comprises 1,3-diene, or 1,5-diene within the fused four-ring system;

and K is $-\text{C}(\text{O})-$, $=\text{CR}^1-$ or $-\text{CR}^1\text{R}^2$, wherein R^2 is $-\text{H}$ and R^1 is $-\text{OR}^{11}$, wherein R^{11} is $-\text{H}$, substituted or unsubstituted alkyl or $-\text{C}(\text{O})\text{R}^{12}$, wherein R^{12} is substituted or unsubstituted lower alkyl;

A is $-\text{CR}^9\text{R}^{10}$, wherein R^9 is $-\text{OH}$ or substituted or unsubstituted lower alkoxy and R^{10} is substituted or unsubstituted lower alkynyl.

55. (currently amended). The compound of claim 4 54, wherein the fused ring system is a 1,6-diene and G is $=\text{CR}^3$, wherein R^3 is $-\text{H}$, $-\text{OH}$, or substituted or unsubstituted lower alkoxy.

56. (currently amended) A The compound ~~having the structure II of claim~~ 54




a prodrug of the compound, a pharmaceutically acceptable salt of the compound, a stereoisomer of the compound, a tautomer of the compound, or a solvate of the compound

wherein the dashed lines in structure II IA represent carbon-carbon double bonds or carbon-carbon single bonds contained within the fused four-ring system, such that the compound comprises a 1,3-diene, or 1,5-diene within the fused four-ring system and G is $-\text{C}(\text{O})-$ or $-\text{CR}^3\text{R}^4$.

57. (currently amended) The compound of claim 58 56, wherein the fused ring system is a 1,5-diene.

58. (currently amended) A compound having the structure IIA IB



IIA IB

wherein,

X and Y are -O- or -S-;


Z is optionally substituted C2-C4 alkyl;

each R^{16} R^{11} is independently -H or $C(O)-R^{16}-C(O)R^{12}$; wherein R^{16} R^{12} is lower alkyl;

and the dashed lines in structure IIA IB represent carbon-carbon double bonds or carbon-carbon single bonds contained within the fused four-ring system, such that the compound comprises a 1,3-diene, or 1,5-diene within the fused four-ring system.

59. (previously presented) The compound of claim 58, wherein both R^{11} are $-C(O)-CH_3$; and the compound comprises a 1,5-diene within the fused four-ring system.

60. (currently amended) A The compound of claim 57 having the structure-



wherein G is -C(O)- or -CR³R⁴-, wherein R³ is -H and R⁴ is -OH.

61. (currently amended) A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and at least one compound of claims 54 or ~~claim 56~~ or 62.

62. (new) The compound of claim 57

wherein G is -CR³R⁴-, wherein R³ is -H and R⁴ is -OH;

K is -CR¹R²-, wherein R¹ is -OR¹¹ wherein R¹¹ is -H or -C(O)R¹² wherein R¹² is unsubstituted lower alkyl; A is -CR⁹R¹⁰-, wherein R⁹ is -H and R¹⁰ is unsubstituted lower alkyl.

63. (new) The compound of claim 62 having the structure

